

Patrick Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046888/publications.pdf>

Version: 2024-02-01

172
papers

8,513
citations

53794

45
h-index

53230

85
g-index

179
all docs

179
docs citations

179
times ranked

10741
citing authors

#	ARTICLE	IF	CITATIONS
1	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	27.6	826
2	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
3	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
4	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	7.7	386
5	Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. <i>Blood</i> , 2010, 115, 5005-5011.	1.4	325
6	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 1031-1043.	0.9	193
7	Surgery for primary CNS lymphoma? Challenging a paradigm. <i>Neuro-Oncology</i> , 2012, 14, 1481-1484.	1.2	192
8	A specific miRNA signature in the peripheral blood of glioblastoma patients. <i>Journal of Neurochemistry</i> , 2011, 118, 449-457.	3.9	177
9	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	7.7	176
10	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018, 20, 445-456.	1.2	173
11	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	1.6	159
12	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
13	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	7.1	135
14	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , 2016, 18, now133.	1.2	130
15	GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. <i>Clinical Cancer Research</i> , 2010, 16, 3851-3859.	7.0	125
16	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	10.1	125
17	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. <i>Journal of Neurochemistry</i> , 2012, 122, 444-455.	3.9	120
18	Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105

#	ARTICLE	IF	CITATIONS
19	High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. <i>Molecular Oncology</i> , 2019, 13, 2305-2328.	4.6	100
20	Integrin control of the transforming growth factor- β pathway in glioblastoma. <i>Brain</i> , 2013, 136, 564-576.	7.6	94
21	Integrin isoform expression in primary human tumors and brain metastases. <i>International Journal of Cancer</i> , 2013, 133, 2362-2371.	5.1	94
22	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. <i>Neurology</i> , 2015, 84, 1242-1248.	1.1	94
23	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019, 21, 648-658.	1.2	90
24	Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1. <i>Cancer Research</i> , 2007, 67, 3540-3544.	0.9	87
25	Steroids in neurooncology: actions, indications, side-effects. <i>Current Opinion in Neurology</i> , 2010, 23, 597-602.	3.6	85
26	Biological activity of tumor-treating fields in preclinical glioma models. <i>Cell Death and Disease</i> , 2017, 8, e2753-e2753.	6.3	79
27	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. <i>Oncotarget</i> , 2014, 5, 7651-7662.	1.8	79
28	Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. <i>Neuro-Oncology</i> , 2014, 16, viii14-viii19.	1.2	77
29	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , 2016, 122, 2206-2215.	4.1	77
30	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017, 130, 1-9.	4.4	76
31	Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. <i>Neurology</i> , 2012, 79, 890-896.	1.1	73
32	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 882-895.	7.0	73
33	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. <i>Journal of Neuro-Oncology</i> , 2010, 97, 389-392.	2.9	72
34	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. <i>Journal of Controlled Release</i> , 2019, 295, 130-139.	9.9	72
35	Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. <i>Neuro-Oncology</i> , 2014, 16, 584-588.	1.2	70
36	Immunocytokines are a promising immunotherapeutic approach against glioblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	69

#	ARTICLE	IF	CITATIONS
37	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016, 7, 15018-15032.	1.8	62
38	How we treat glioblastoma. <i>ESMO Open</i> , 2019, 4, e000520.	4.5	62
39	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016, 18, 744-751.	1.2	58
40	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. <i>Oncotarget</i> , 2016, 7, 12937-12950.	1.8	58
41	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1815-1821.	2.5	57
42	Prioritizing and selecting likely novel miRNAs from NGS data. <i>Nucleic Acids Research</i> , 2016, 44, e53-e53.	14.5	52
43	Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncology Practice</i> , 2015, 2, 6-12.	1.6	51
44	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. <i>Journal of the National Cancer Institute</i> , 2017, 109, 1-4.	6.3	51
45	Interferon- β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 948-961.	4.1	47
46	Biological Role and Therapeutic Targeting of TGF- β 3 in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1177-1186.	4.1	47
47	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 1016-1021.	1.2	46
48	A tissue-based draft map of the murine MHC class I immunopeptidome. <i>Scientific Data</i> , 2018, 5, 180157.	5.3	45
49	Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1338-1349.	1.2	44
50	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. <i>Journal of Neuro-Oncology</i> , 2009, 92, 45-48.	2.9	43
51	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. <i>Neuro-Oncology</i> , 2011, 13, 155-164.	1.2	42
52	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
53	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2055.	1.6	42
54	Tumor-associated edema in brain cancer patients: pathogenesis and management. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1319-1325.	2.4	41

#	ARTICLE	IF	CITATIONS
55	Control of glioma cell migration and invasiveness by GDF-15. <i>Oncotarget</i> , 2016, 7, 7732-7746.	1.8	40
56	HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. <i>Journal of Neuroimmunology</i> , 2012, 250, 27-34.	2.3	39
57	Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1007-1015.	1.2	38
58	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , 2018, 135, 923-938.	7.7	36
59	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	7.7	34
60	Therapeutic Targeting of TGF β Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 7189-7201.	7.0	33
61	Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. <i>Neuro-Oncology</i> , 2017, 19, now265.	1.2	32
62	Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. <i>European Journal of Cancer</i> , 2015, 51, 382-390.	2.8	31
63	Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. <i>Journal of Neurosurgery</i> , 2010, 113, 280-285.	1.6	30
64	Challenges in the treatment of elderly patients with primary central nervous system lymphoma. <i>Current Opinion in Neurology</i> , 2014, 27, 697-701.	3.6	30
65	Immunological effects of chemotherapy and radiotherapy against brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1087-1094.	2.4	30
66	Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	7.0	30
67	Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 165-171.	2.9	28
68	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	4.1	28
69	Direct contact with perivascular tumor cells enhances integrin α β 3 signaling and migration of endothelial cells. <i>Oncotarget</i> , 2016, 7, 43852-43867.	1.8	28
70	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. <i>Blood</i> , 2018, 132, 2744-2753.	1.4	27
71	Risk factors for the development of epilepsy in patients with brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 718-728.	1.2	27
72	Geriatric neuro-oncology. <i>Current Opinion in Neurology</i> , 2011, 24, 599-604.	3.6	25

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for glioblastoma. <i>Current Opinion in Neurology</i> , 2015, 28, 639-646.	3.6	25
74	Management of neoplastic meningitis. <i>Chinese Clinical Oncology</i> , 2015, 4, 26.	1.2	25
75	Regeneration and Tolerance Factor: A Novel Mediator of Glioblastoma-Associated Immunosuppression. <i>Cancer Research</i> , 2006, 66, 3852-3858.	0.9	24
76	Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1259-1270.	1.8	24
77	Transcriptional control of O ⁶ -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. <i>Journal of Neurochemistry</i> , 2018, 144, 780-790.	3.9	24
78	Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> , 2016, 16, 287.	2.6	23
79	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. <i>Cell Death and Disease</i> , 2021, 12, 885.	6.3	22
80	Anticoagulation for radiation-induced neurotoxicity revisited. <i>Journal of Neuro-Oncology</i> , 2008, 90, 357-362.	2.9	21
81	Pathogenesis and management of primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 623-633.	2.4	21
82	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 82028-82045.	1.8	21
83	A series of patients with subpial hemorrhage: Clinical manifestation, neuroradiological presentation and therapeutic implications. <i>Journal of Neurology</i> , 2008, 255, 1018-1022.	3.6	19
84	SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 6609-6618.	7.0	19
85	Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. <i>Annals of Hematology</i> , 2015, 94, 409-414.	1.8	19
86	Closed-loop cavitation control for focused ultrasound-mediated blood-brain barrier opening by long-circulating microbubbles. <i>Physics in Medicine and Biology</i> , 2019, 64, 045012.	3.0	18
87	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2004-2004.	1.6	18
88	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
89	Treatment of Primary CNS Lymphoma. <i>Current Treatment Options in Neurology</i> , 2014, 16, 277.	1.8	17
90	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	2.8	17

#	ARTICLE	IF	CITATIONS
91	Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. <i>Current Treatment Options in Oncology</i> , 2013, 14, 505-513.	3.0	16
92	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 179-188.	7.0	16
93	How Stemlike Are Sphere Cultures From Long-term Cancer Cell Lines? Lessons From Mouse Glioma Models. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 1062-1077.	1.7	15
94	Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. <i>Cancers</i> , 2021, 13, 3073.	3.7	15
95	Immunology of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 45-51.	1.8	14
96	Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 326-334.	1.2	14
97	Survival of brain tumour patients with epilepsy. <i>Brain</i> , 2021, 144, 3322-3327.	7.6	14
98	Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. <i>Chemotherapy</i> , 2014, 60, 375-378.	1.6	13
99	ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. <i>Neuro-Oncology</i> , 2015, 17, v34.3-v34.	1.2	13
100	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2003-2003.	1.6	13
101	Seizure-Induced Periorbital Petechial Rash. <i>European Neurology</i> , 2009, 61, 317-317.	1.4	12
102	Management of Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 35.	4.2	12
103	Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. <i>International Journal of Pharmaceutics</i> , 2018, 536, 388-396.	5.2	12
104	End-of-life care for glioma patients; the caregivers' perspective. <i>Journal of Neuro-Oncology</i> , 2020, 147, 663-669.	2.9	12
105	Interferon- β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. <i>PLoS ONE</i> , 2015, 10, e0139603.	2.5	11
106	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
107	Socioeconomic burden and quality of life in meningioma patients. <i>Quality of Life Research</i> , 2020, 29, 1801-1808.	3.1	11
108	Telomerase reverse transcriptase promoter mutation and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94.	2.8	10

#	ARTICLE	IF	CITATIONS
109	Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. <i>Acta Oncologica</i> , 2014, 53, 1436-1440.	1.8	9
110	A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 87-100.	3.4	9
111	Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas. <i>Blood</i> , 2014, 124, 142-142.	1.4	9
112	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2001-2001.	1.6	9
113	Management of diffusely infiltrating glioma in the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 502-509.	2.4	8
114	Complementary and alternative medicine use by glioma patients in Switzerland. <i>Neuro-Oncology Practice</i> , 2019, 6, 237-244.	1.6	8
115	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 339-347.	2.9	7
116	Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2021-2021.	1.6	7
117	Venous thromboembolic events in glioblastoma patients: An epidemiological study. <i>European Journal of Neurology</i> , 2022, 29, 2386-2397.	3.3	7
118	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2072-TPS2072.	1.6	6
119	ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi20.	1.2	5
120	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. <i>Swiss Medical Weekly</i> , 2020, 150, w20256.	1.6	5
121	Antidepressant drug use in glioblastoma patients: an epidemiological view. <i>Neuro-Oncology Practice</i> , 2020, 7, 514-521.	1.6	4
122	A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14083-e14083.	1.6	4
123	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019, 21, vi12-vi12.	1.2	3
124	Interferon- β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa043.	0.7	3
125	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	1.6	3
126	Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2032-2032.	1.6	3

#	ARTICLE	IF	CITATIONS
127	Targeting glioblastoma with novel immunocytokines.. Journal of Clinical Oncology, 2020, 38, 2558-2558.	1.6	3
128	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	1.6	2
129	The molecular evolution of glioblastoma treated by gross total resection alone. Neuro-Oncology, 2021, 23, 334-336.	1.2	2
130	Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2092-2092.	1.6	2
131	Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. Journal of Clinical Oncology, 2015, 33, e13025-e13025.	1.6	2
132	Prognostic Relevance of Transforming Growth Factor- β Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype. Journal of Neuropathology and Experimental Neurology, 2022, 81, 225-235.	1.7	2
133	IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS. Neuro-Oncology, 2018, 20, vi133-vi133.	1.2	1
134	RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, vi240-vi240.	1.2	1
135	ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA,) Tj ETQq1.1 0.784314 rgBT		
136	Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice, 2021, 8, 475-484.	1.6	1
137	Neuro-Oncology Practice in 2021: Covid-19, telemedicine, and beyond. Neuro-Oncology Practice, 2021, 8, 107-108.	1.6	1
138	The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2068-TPS2068.	1.6	1
139	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. Neuro-Oncology, 2021, 23, 1612-1613.	1.2	1
140	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.. Journal of Clinical Oncology, 2017, 35, 2014-2014.	1.6	1
141	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	1.2	1
142	Clinical Reasoning: A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades. Neurology, 2014, 82, e56-60.	1.1	0
143	New frontiers in neurooncology. Current Opinion in Neurology, 2015, 28, 626-627.	3.6	0
144	ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERSâ€™™ COLLABORATIVE CONSORTIUM. Neuro-Oncology, 2016, 18, vi5-vi5.	1.2	0

#	ARTICLE	IF	CITATIONS
145	RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi235-vi236.	1.2	0
146	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi48-vi49.	1.2	0
147	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi14.	1.2	0
148	QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi220-vi220.	1.2	0
149	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. <i>Neuro-Oncology</i> , 2019, 21, vi76-vi76.	1.2	0
150	IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi122.	1.2	0
151	SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE. <i>Neuro-Oncology Advances</i> , 2021, 3, iv8-iv9.	0.7	0
152	Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2007-2007.	1.6	0
153	Induction of atypical anoikis in glioma cells through inhibition of integrin functions.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2079-2079.	1.6	0
154	Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13505-e13505.	1.6	0
155	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2076-2076.	1.6	0
156	Constitutive IFN signaling to modulate the immunogenicity of glioma cells.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13528-e13528.	1.6	0
157	Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2013-2013.	1.6	0
158	Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14061-e14061.	1.6	0
159	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14062-e14062.	1.6	0
160	Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13546-e13546.	1.6	0
161	Safety, Tolerability, and Use of Steroids. , 2020, , 127-137.		0
162	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14530-e14530.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2548-2548.	1.6	0
164	The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2520-2520.	1.6	0
165	DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi78-vi79.	1.2	0
166	IMMU-13. COMBINED MODULATION OF THE TGF- β PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS. Neuro-Oncology, 2021, 23, vi94-vi94.	1.2	0
167	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi101-vi101.	1.2	0
168	EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi167-vi168.	1.2	0
169	IMMU-07. TUMOR STROMAâ€™s TARGETING ANTIBODY-CYTOKINE CONJUGATES TO CONVERT THE IMMUNOLOGICALLY COLD GLIOMA MICROENVIRONMENT INTO A HOT ONE. Neuro-Oncology, 2020, 22, ii106-ii106.	1.2	0
170	EPID-36. ANTIDEPRESSANT DRUG USE IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. Neuro-Oncology, 2020, 22, ii86-ii86.	1.2	0
171	BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?. Neuro-Oncology, 2020, 22, ii14-ii14.	1.2	0
172	Treatment of gliomas with temozolomide: rather at sunrise or sunset?. Neuro-Oncology Practice, 0, , .	1.6	0